Global Sexually Transmitted Diseases (STD) Testing Market to Reach $150.44 Billion by 2030: AMR

The market across Asia-Pacific is expected to manifest the highest CAGR of 5.3% from 2021 to 2030. Moreover, the region is expected to continue its dominance in terms of revenue generation throughout the forecast period.

As per the report published by Allied Market Research, the global sexually transmitted diseases (STD) testing market is expected to garner $150.44 billion by 2030, registering a CAGR of 5.1% from 2021 to 2030. The report highlights the market potential, market characteristics, growth by segmentation, and competitive landscape.

According to the report, high prevalence and increase in incidences of STDs, supporting reimbursement for STD testing and implementation of national screening programs drive the growth of the global sexually transmitted diseases (STD) testing market. However, a huge proportion of patients infected with STDs in remote areas, a rise in the number of patients infected with STDs in remote areas, stringent regulatory abidance requirements for participants in the STD market, and social stigma associated with patients visiting specialized STD clinics hamper the market growth. On the contrary, a reduction in the number of visits to government clinics, advancements in technology and POC tests, and national screening programs would open new opportunities in the future.

Covid-19 pandemic impact on the market:

The Covid-19 outbreak and followed pandemic had an adverse impact on the market owing to a decline in the number of STD cases and disruptions in the healthcare sector. Moreover, during the pandemic, non-urgent visits and preventive services were reduced in order to preserve personal protective equipment supply.

The global sexually transmitted diseases (STD) testing market is analyzed across several regions such as Europe, North America, Asia-Pacific, and LAMEA. The market across Asia-Pacific is expected to manifest the highest CAGR of 5.3% from 2021 to 2030. Moreover, the region is expected to continue its dominance in terms of revenue generation throughout the forecast period.

The global sexually transmitted diseases (STD) testing market is segmented based on disease type and location of testing.

Based on disease type, the gonorrhea segment would portray the highest CAGR of 7.3% from 2021 to 2030. However, the chlamydia testing segment would hold the lion’s share throughout the study period.

On the basis of the location of testing, the point of care segment would register the highest CAGR of 6.3% during the forecast period. However, the laboratory testing segment is expected to hold the largest share during the forecast period.

The global sexually transmitted diseases (STD) testing market report includes an in-depth analysis of the major market players such as Abbott Laboratories, Becton Dickinson Company, BioMérieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Diasorin Molecular LLC, Hologic, Inc., Orasure Technologies, Inc., Roche Holding AG, and Thermo Fisher Scientific Inc.